Skip to main content
SpringerLink
Log in

Early-Invasive Urothelial Bladder Carcinoma and Instillation Treatment of Non-muscle-Invasive Bladder Cancer

  • Reference work entry
  • First Online:
Urologic Oncology

Abstract

Stage T1 non-muscle-invasive bladder cancer (NMIBC) is a very special subentity of urothelial bladder carcinoma showing progression in up to 50% within 5 years after first diagnosis. This chapter recalls recommended diagnosis and treatment of early-invasive bladder cancer in special and conservative adjuvant instillation treatment of NMIBC in general. In the end, indications of immediate and early cystectomy of NMIBC are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 599.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 899.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aaronson DS, Walsh TJ, Smith JF, Davies BJ, Hsieh MH, Konety BR. Meta-analysis: does lidocaine gel before flexible cystoscopy provide pain relief? BJU Int. 2009;104(4):506–9; discussion 509–10.

    Article  CAS  Google Scholar 

  • Agarwal PK, Black PC, Kamat AM. Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol. 2008;26(1):39–44.

    Article  Google Scholar 

  • Aziz A, May M, Burger M, Palisaar RJ, Trinh QD, Fritsche HM, Rink M, Chun F, Martini T, Bolenz C, Mayr R, Pycha A, Nuhn P, Stief C, Novotny V, Wirth M, Seitz C, Noldus J, Gilfrich C, Shariat SF, Brookman-May S, Bastian PJ, Denzinger S, Gierth M, Roghmann F, PROMETRICS 2011 research group. Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort. Eur Urol. 2014;66(1):156–63.

    Article  Google Scholar 

  • Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2016; https://doi.org/10.1016/j.eururo.2016.05.041.

    Article  Google Scholar 

  • Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169(1):90–5.

    Article  Google Scholar 

  • Bol MG, Baak JP, Buhr-Wildhagen S, Kruse AJ, Kjellevold KH, Janssen EA, Mestad O, Øgreid P. Reproducibility and prognostic variability of grade and lamina propria invasion in stages ta, T1 urothelial carcinoma of the bladder. J Urol. 2003;169(4):1291–4.

    Article  Google Scholar 

  • Casey RG, Catto JW, Cheng L, Cookson MS, Herr H, Shariat S, Witjes JA, Black PC. Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. Eur Urol. 2015;67(5):876–88.

    Article  Google Scholar 

  • Denzinger S, Fritsche HM, Otto W, Blana A, Wieland WF, Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol. 2008;53:146–52.

    Article  Google Scholar 

  • Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Montesinos M, Isorna S, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195–203.

    Article  Google Scholar 

  • Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol. 2003;169(6):1975–82.

    Article  Google Scholar 

  • Goessl C, Knispel HH, Miller K, Klän R. Is routine excretory urography necessary at first diagnosis of bladder cancer? J Urol. 1997;157(2):480–1.

    Article  CAS  Google Scholar 

  • Golijanin D, Yossepowitch O, Beck SD, Sogani P, Dalbagni G. Carcinoma in a bladder diverticulum: presentation and treatment outcome. J Urol. 2003;170(5):1761–4.

    Article  Google Scholar 

  • Hautmann RE, Volkmer BG, Gust K. Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J Urol. 2009;27(3):347–51.

    Article  Google Scholar 

  • Hinotsu S, Akaza H, Ohashi Y, Kotake T. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese urological Cancer research group using smoothed hazard function. Cancer. 1999;86(9): 1818–26.

    Article  CAS  Google Scholar 

  • Holmäng S, Hedelin H, Anderström C, Holmberg E, Johansson SL. Long-term followup of a bladder carcinoma cohort: routine followup urography is not necessary. J Urol. 1998;160(1):45–8.

    Article  Google Scholar 

  • Huncharek M, Geschwind JF, Witherspoon B, McGarry R, Adcock D. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol. 2000;53(7):676–80.

    Article  CAS  Google Scholar 

  • Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res. 2001;21(1B):765–9.

    CAS  PubMed  Google Scholar 

  • Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol. 2009;56(2):260–5.

    Article  Google Scholar 

  • Jinzaki M, Kikuchi E, Akita H, Sugiura H, Shinmoto H, Oya M. Role of computed tomography urography in the clinical evaluation of upper tract urothelial carcinoma. Int J Urol. 2016;23(4):284–98.

    Article  Google Scholar 

  • Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, Lotan Y, Kassouf W. Bladder cancer. Lancet. 2016;23(16):30512–8. https://doi.org/10.1016/S0140-6736(16)30512-8.

    Article  Google Scholar 

  • Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P, Jocham D, Ziegler A, Vonthein R. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol. 2010;57(4):595–606.

    Article  Google Scholar 

  • Krogsboll LT, Jorgensen KJ, Gotzsche PC. Screening with urinary dipsticks for reducing morbidity and mortality. Cochrane Database Syst Rev. 2015;1:CD010007.

    PubMed  Google Scholar 

  • Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W, Kamat A, Zlotta A. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol. 2010;57(1):60–70.

    Article  Google Scholar 

  • Kurth KH, Schellhammer PF, Okajima E, Akdas A, Jakse G, Herr HW, Calais da Silva F, Fukushima S, Nagayama T. Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. Int J Urol. 1995;2(Suppl 2):8–22.

    Article  Google Scholar 

  • Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol. 2000;163(4):1124–9.

    Article  CAS  Google Scholar 

  • Layfield LJ, Elsheikh TM, Fili A, Nayar R, Shidham V, Papanicolaou Society of Cytopathology. Review of the state of the art and recommendations of the Papanicolaou Society of Cytopathology for urinary cytology procedures and reporting : the Papanicolaou Society of Cytopathology Practice Guidelines Task Force. Diagn Cytopathol. 2004;30(1):24–30.

    Article  Google Scholar 

  • Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ. Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers. Urology. 2005;66(6 Suppl 1):35–63.

    Article  Google Scholar 

  • Lotan Y, Shariat SF, Schmitz-Dräger BJ, Sanchez-Carbayo M, Jankevicius F, Racioppi M, Minner SJ, Stöhr B, Bassi PF, Grossman HB. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol. 2010;28(4): 441–8.

    Article  Google Scholar 

  • Mangrud OM, Waalen R, Gudlaugsson E, Dalen I, Tasdemir I, Janssen EA, Baak JP. Reproducibility and prognostic value of WHO1973 and WHO2004 grading systems in TaT1 urothelial carcinoma of the urinary bladder. PLoS One. 2014;9(1):e83192.

    Article  Google Scholar 

  • Mansson A, Anderson H, Colleen S. Time lag to diagnosis of bladder cancer – influence of psychosocial parameters and level of health-care provision. Scand J Urol Nephrol. 1993;27:363–9.

    Article  CAS  Google Scholar 

  • May M, Brookman-Amissah S, Roigas J, Hartmann A, Störkel S, Kristiansen G, Gilfrich C, Borchardt R, Hoschke B, Kaufmann O, Gunia S. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol. 2010;57(5):850–8.

    Article  Google Scholar 

  • Mikulowski P, Hellsten S. T1 G1 urinary bladder carcinoma: fact or fiction? Scand J Urol Nephrol. 2005;39(2):135–7.

    Article  Google Scholar 

  • Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Huguet-Pérez J, Vicente-Rodríguez J. Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. J Urol. 2000;164(4):1183–7.

    Article  Google Scholar 

  • Murphy WM, Takezawa K, Maruniak NA. Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care. J Urol. 2002;168(3):968–72.

    Article  Google Scholar 

  • Nolte-Ernsting C, Cowan N. Understanding multislice CT urography techniques: many roads lead to Rome. Eur Radiol. 2006;16(12):2670–86.

    Article  Google Scholar 

  • Otto W, Burger M, Fritsche HM, Blana A, Roessler W, Knuechel R, Wieland WF, Denzinger S. Photodynamic diagnosis for superficial bladder cancer: do all risk-groups profit equally from oncological and economic long-term results? Clin Med Oncol. 2009;3:53–8.

    PubMed  PubMed Central  Google Scholar 

  • Otto W, Denzinger S, Fritsche HM, Burger M, Wieland WF, Hofstädter F, Hartmann A, Bertz S. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int. 2011;107(3):404–8.

    Article  Google Scholar 

  • Palou J, Rodríguez-Rubio F, Huguet J, Segarra J, Ribal MJ, Alcaraz A, Villavicencio H. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol. 2005;174(3):859–61; discussion 861.

    Article  Google Scholar 

  • Patschan O, Holmäng S, Hosseini A, Jancke G, Liedberg F, Ljungberg B, Malmström PU, Rosell J, Jahnson S. Second-look resection for primary stage T1 bladder cancer: a population-based study. Scand J Urol. 2017;51(4):301–7.

    Article  Google Scholar 

  • Raitanen MP, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, Tammela TL, FinnBladder Group. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol. 2002;41(3):284–9.

    Article  Google Scholar 

  • Razavi SA, Sadigh G, Kelly AM, Cronin P. Comparative effectiveness of imaging modalities for the diagnosis of upper and lower urinary tract malignancy: a critically appraised topic. Acad Radiol. 2012;19(9):1134–40.

    Article  Google Scholar 

  • Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol. 2003;169(1):96–100; discussion 100.

    Article  CAS  Google Scholar 

  • Sharp VJ, Barnes KT, Erickson BA. Assessment of asymptomatic microscopic hematuria in adults. Am Fam Physician. 2013;88(11):747–54.

    PubMed  Google Scholar 

  • Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–5; discussion 475–7.

    Article  Google Scholar 

  • Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol. 2008;53(4):709–19.

    Article  CAS  Google Scholar 

  • Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkali Z, van de Beek C, Gorlia T, de Reijke TM. EORTC Genito-Urinary Tract Cancer Group. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57(5): 766–73.

    Article  Google Scholar 

  • van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol. 2005;47(6):736–48.

    Article  Google Scholar 

  • van Rhijn BW, van der Kwast TH, Kakiashvili DM, Fleshner NE, van der Aa MN, Alkhateeb S, Bangma CH, Jewett MA, Zlotta AR. Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int. 2010a;106(2):206–11.

    Article  Google Scholar 

  • van Rhijn BW, van Leenders GJ, Ooms BC, Kirkels WJ, Zlotta AR, Boevé ER, Jöbsis AC, van der Kwast TH. The pathologist’s mean grade is constant and individualizes the prognostic value of bladder cancer grading. Eur Urol. 2010b;57(6):1052–7.

    Article  Google Scholar 

  • Vikram R, Sandler CM, Ng CS. Imaging and staging of transitional cell carcinoma: part 2, upper urinary tract. AJR Am J Roentgenol. 2009;192(6):1488–93.

    Article  Google Scholar 

  • Vrooman OP, Witjes JA. Urinary markers in bladder cancer. Eur Urol. 2008;53(5):909–16.

    Article  Google Scholar 

  • Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol. 2015;33(2):66.e25–31.

    Article  Google Scholar 

  • Yutkin V, Nisman B, Pode D. Can urinary biomarkers replace cystoscopic examination in bladder cancer surveillance? Expert Rev Anticancer Ther. 2010;10(6): 787–90.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Caritas-St. Josef Medical Center, University of Regensburg, Regensburg, Germany

    Wolfgang Otto, Maximilian Burger & Johannes Breyer

Authors
  1. Wolfgang Otto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maximilian Burger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Johannes Breyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang Otto .

Editor information

Editors and Affiliations

  1. Department of Urology, University Hospital Schleswig-Holstein Campus Lübeck, Lübeck, Germany

    Axel S. Merseburger

  2. Department of Urology, Caritas-St. Josef Medical Center, University of Regensburg, Regensburg, Germany

    Maximilian Burger

Section Editor information

  1. Department of Urology, University of Regensburg, Regensburg, Germany

    Wolfgang Otto

  2. Departement of Urology, Weill Cornell Medical Center, New York, NY, USA

    Shahrokh F. Shariat

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Otto, W., Burger, M., Breyer, J. (2019). Early-Invasive Urothelial Bladder Carcinoma and Instillation Treatment of Non-muscle-Invasive Bladder Cancer. In: Merseburger, A., Burger, M. (eds) Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-42623-5_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42623-5_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42622-8

  • Online ISBN: 978-3-319-42623-5

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation